CO67 Tafasitamab Plus Lenalidomide (TAFA+LEN) Versus Pola-BR, R2, and CAR-T in Non-Transplant Eligible (NTE) Relapsed/Refractory (R/R) DLBCL: A Post Hoc Analysis of the RE-MIND2 Study Comparing Multiple Cohort-Balancing Approaches

Autor: Córdoba, R, Zinzani, PL, Joffe, E, Yoon, DH, Peters, A, Waltl, EE, Alvero, C, Sabatelli, L, Salles, G, Nowakowski, GS
Zdroj: In Value in Health December 2022 25(12) Supplement:S30-S30
Databáze: ScienceDirect
Externí odkaz: